US Zamto-cel Autoimmune Diseases

NCT ID: NCT06708845

Last Updated: 2024-11-27

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-31
• Study Completion Date: 2026-12-31

Brief Summary

AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.

Detailed Description

This is a Phase 1, multicohort, dose-finding study evaluating autologous T cells engineered to target dual CD19 and CD20 antigens in subjects with refractory autoimmune diseases following standard therapy. The investigational product, Zamto-cel, is a chimeric antigen receptor T-cell (CAR-T) therapy genetically engineered to enable subjects' T cells to express CARs on their surfaces.

Eligible subjects will undergo leukapheresis for the collection of cells required for manufacturing. Prior to infusion of the fresh CAR-T product, subjects will receive a lymphodepleting regimen consisting of cyclophosphamide and fludarabine. The CAR-T cell infusion will be administered intravenously at a dose of 2.5 x 10^6 or 1.0 x 10^6 CAR+ cells/kg body weight, based on the dose level assigned to the cohort.

The study will initially enroll 3 subjects per cohort in a staggered manner to evaluate safety. Upon confirmation of safety, the study will proceed to cohort-specific recommended Phase 2 dose (RP2D) and dose expansion phases. Subjects will be monitored for up to 1 year to assess safety, preliminary efficacy, and health-related quality of life (HRQoL). Additional long-term follow-up will be conducted under a separate long-term follow-up protocol.

Conditions

Lupus Nephritis; Systemic Lupus Erythematosus; Systemic Sclerosis (SSc); Diffuse Cutaneous Systemic Sclerosis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose Level 1

Group Type: EXPERIMENTAL

zamtocabtagene autoleucel

Intervention Type: BIOLOGICAL

chimeric antigen receptor T-cell (CAR-T) therapy

Cyclophosphamide

Intervention Type: DRUG

Lymphodepleting chemotherapy

Fludarabine

Intervention Type: DRUG

Lymphodepleting chemotherapy

Dose Level 2

Group Type: EXPERIMENTAL

zamtocabtagene autoleucel

Intervention Type: BIOLOGICAL

chimeric antigen receptor T-cell (CAR-T) therapy

Cyclophosphamide

Intervention Type: DRUG

Lymphodepleting chemotherapy

Fludarabine

Intervention Type: DRUG

Lymphodepleting chemotherapy

Interventions

zamtocabtagene autoleucel

chimeric antigen receptor T-cell (CAR-T) therapy

Intervention Type: BIOLOGICAL

Cyclophosphamide

Lymphodepleting chemotherapy

Intervention Type: DRUG

Fludarabine

Lymphodepleting chemotherapy

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

•Confirmed diagnosis of autoimmune disease (SLE-Non-renal, SLE-LN, SSc/ dcSSc)

• Positive for at least 1 of the following autoantibodies at Screening: anti- double stranded DNA or anti-Smith
• Systemic Lupus Erythematosus Disease Activity Index-2000 score ≥ 8 AND at least 1 British Isles Lupus Assessment Group (BILAG)-2004 Class A (severe manifestation) organ scores
• Inadequate response to glucocorticoids and to at least 2 of the following treatments, used for at least 3 months each: cyclophosphamide, mycophenolic acid or its derivatives, belimumab, azathioprine, anifrolumab, methotrexate, rituximab, or obinutuzumab

• Positive for at least 1 of the following autoantibodies at Screening: anti- double stranded DNA or anti-Smith
• Confirmed LN diagnosis by kidney biopsy during screening or within the previous 6 months, with severe active phase of the disease.
• Progressing despite maintenance on maximally tolerated doses of renin- angiotensin system (RAS) blocking agents, unless allergic to or intolerant of ACE inhibitors and ARBs
• Inadequate response to glucocorticoids and hydroxychloroquine and at least 1 of the following treatments, used for at least 3 months each: cyclophosphamide, mycophenolic acid derivatives, belimumab, azathioprine, methotrexate, rituximab, obinutuzumab, calcineurin inhibitor (cyclosporin, tacrolimus or voclosporin)

• Active disease defined as:
• Modified Rodnan skin score (mRSS) ≥ 16 units, in the prior 6 months, with 1 or more of the following:

• Increase in mRSS by ≥ 3 units or 10%
• Involvement of 1 new body area with increase in mRSS by ≥ 2 units
• Involvement of 2 new body areas with increase by ≥ 1 mRSS unit OR
• Progressive interstitial lung disease (ILD) defined as:

• Worsening of respiratory symptoms and an increased extent of fibrosis evaluated by high-resolution computed tomography
• Lack of response to standard therapy (e.g., failure of ≥ 2 immunosuppressive therapies)

Exclusion Criteria

• Prior gene therapy treatment
• Active malignancy within past 5 years
• Significant active fungal or bacterial infection
• History or presence of CNS lupus or other CNS disease
• eGFR < 45 mL/min/1.73 m^2
• Total bilirubin outside the normal range (unless congenital hyperbilirubinemia such as Gilbert syndrome has been confirmed).

• Subjects with neuropsychiatric SLE.
• Drug-induced SLE.

•Evidence of Rapidly progressive glomerulonephritis (defined as a doubling of serum creatinine within 3 months prior to enrollment) or as determined by the study investigator.

• "Active" gastric antral vascular ectasia, as evidenced by bleeding (ie, on esophagogastroduodenoscopy) in the past 6 months or as per Investigator's assessment.
• History of SSc renal crisis within 1 year prior to Screening; presence of kidney impairment due to conditions other than SSc

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Miltenyi Biomedicine GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Esther Eromosele, MD

Role: STUDY_DIRECTOR

Miltenyi Biomedicine

Central Contacts

Sadie Swift

Role: CONTACT

clinicaltrials@miltenyi.com

617-218-0044

Ron Gomez

Role: CONTACT

clinicaltrials@miltenyi.com

617-218-0044

Other Identifiers

M-2024-423

Identifier Type: -

Identifier Source: org_study_id